1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1'-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole | 882037-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1'-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole
• 英文别名: 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1"-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole；1-(3-amino-1,2-benzoxazol-5-yl)-N-{2-fluoro-4-[2-(piperazin-1-ylmethyl)phenyl]phenyl}-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide；2-(3-amino-1,2-benzoxazol-5-yl)-N-[2-fluoro-4-[2-(piperazin-1-ylmethyl)phenyl]phenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
• CAS: 882037-20-9
• 化学式: C₂₉H₂₅F₄N₇O₂
• 分子量: 579.557
• InChiKey: HMOHJEKAKRIFLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1'-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole 、 三氟乙酸 生成 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1"-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole trifluoroacetate
  参考文献：
  名称：

  Guanidine mimics as factor Xa inhibitors

  摘要：

  本申请描述了含氮杂环化合物及其衍生物的化学式I：或其药用可接受的盐形式，其中环D—E代表胍嘧啶模拟物，这些化合物可作为凝血因子Xa的抑制剂。

  公开号：

  US06339099B1
• 作为产物：
  描述：

  2-(3-cyano-4-fluoro-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carbonyl chloride 在 盐酸 、 四溴化碳 、 乙酰氧肟酸 、 potassium carbonate 、 三乙胺 、 三苯基膦 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1'-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole
  参考文献：
  名称：

  Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors

  摘要：

  We have previously reported on a series of aminobenzisoxazoles as potent, selective, and orally bioavailable factor Xa inhibitors. which culminated in the discovery of razaxaban. Herein, we describe another approach to improve factor Xa inhibitory potency and pharmacokinetic profile by incorporating basic and water soluble functionalities on the terminal ring of the P4 biaryl group found ill our earlier Xa inhibitors. This approach resulted in a series of potent, selective, and orally bioavailable factor Xa inhibitors. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.010

文献信息

• Guanidine mimics as factor Xa inhibitors
  申请人：DuPont Pharmaceuticals Company

  公开号：US06339099B1

  公开（公告）日：2002-01-15

  The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.

  本申请描述了含氮杂环化合物及其衍生物的化学式I：或其药用可接受的盐形式，其中环D—E代表胍嘧啶模拟物，这些化合物可作为凝血因子Xa的抑制剂。
• Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
  作者：Mimi L. Quan、Qi Han、John M. Fevig、Patrick Y.S. Lam、Steve Bai、Robert M. Knabb、Joseph M. Luettgen、Pancras C. Wong、Ruth R. Wexler

  DOI：10.1016/j.bmcl.2006.01.010

  日期：2006.4

  We have previously reported on a series of aminobenzisoxazoles as potent, selective, and orally bioavailable factor Xa inhibitors. which culminated in the discovery of razaxaban. Herein, we describe another approach to improve factor Xa inhibitory potency and pharmacokinetic profile by incorporating basic and water soluble functionalities on the terminal ring of the P4 biaryl group found ill our earlier Xa inhibitors. This approach resulted in a series of potent, selective, and orally bioavailable factor Xa inhibitors. (C) 2006 Elsevier Ltd. All rights reserved.